CE: Use of Oncology Supportive Care Biosimilars During COVID-19: Clinical Strategies for Pharmacists

Pharmacy Times Health Systems Edition, July 2020, Volume 9, Issue 4

Cancer medications contribute substantially to the cost of health care in the United States, with 8 of the 10 most expensive drugs indicated for the treatment of cancer

THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM COHERUS BIOSCIENCES, INC.

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

• Examine current oncology supportive care biosimilars and the place in clinical practice for granulocyte colony-stimulating factors

• Investigate current challenges surrounding supportive care biosimilars in clinical practice during the COVID-19 pandemic

• Identify safe practices and strategies for appropriate use of supportive care biosimilars in clinical practice during the COVID-19 pandemic

• Explain economic considerations of supportive care agents

FACULTY

Julianna Merten, PharmD, BCPS, BCOP

Ambulatory Care Pharmacist

Assistant Professor of Pharmacy, College of Medicine, Mayo Clinic, Rochester, Minnesota

Chimeric Medical Communications, LLC, Saint Ansgar, Iowa

TARGET AUDIENCE: Oncology, health-system, managed care, specialty, and retail pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: July 15, 2020

EXPIRATION DATE: July 15, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.